Sandra Nuyts

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5048201/publications.pdf

Version: 2024-02-01

128	2,155	21 h-index	43
papers	citations		g-index
181	181	181	3212
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Transoral robotic surgery (<scp>TORS</scp>) using the da Vinci Xi: prospective analysis of feasibility, safety, and outcomes. Head and Neck, 2022, 44, 143-157.	2.0	10
2	A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer. Frontiers in Oncology, 2022, 12, 761428.	2.8	4
3	Virtual monoenergetic micro-CT imaging in mice with artificial intelligence. Scientific Reports, 2022, 12, 2324.	3.3	3
4	An Integrated Approach Reveals DNA Damage and Proteotoxic Stress as Main Effects of Proton Radiation in S. cerevisiae. International Journal of Molecular Sciences, 2022, 23, 5493.	4.1	2
5	Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges. Cancers, 2022, 14, 2587.	3.7	9
6	Obstructive sleep apnea in head and neck cancer survivors. Supportive Care in Cancer, 2021, 29, 279-287.	2.2	12
7	Randomized Clinical Trial on Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinoma: Results on the Quality of Life. Quality of Life Research, 2021, 30, 117-127.	3.1	3
8	Radiation-Induced Sarcomas of the Head and Neck: A Systematic Review. Advances in Therapy, 2021, 38, 90-108.	2.9	18
9	Clinical Progress in Proton Radiotherapy: Biological Unknowns. Cancers, 2021, 13, 604.	3.7	17
10	Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers. International Journal of Molecular Sciences, 2021, 22, 1504.	4.1	15
11	Current indications for adjuvant treatment following transoral laser microsurgery of early and intermediate laryngeal cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 2021, 29, 79-85.	1.8	9
12	Contemporary management of the neck in nasopharyngeal carcinoma. Head and Neck, 2021, 43, 1949-1963.	2.0	4
13	Electrochemotherapy in Mucosal Cancer of the Head and Neck: A Systematic Review. Cancers, 2021, 13, 1254.	3.7	18
14	Photodynamic Therapy as an Alternative Therapeutic Tool in Functionally Inoperable Oral and Oropharyngeal Carcinoma: A Single Tertiary Center Retrospective Cohort Analysis. Frontiers in Oncology, 2021, 11, 626394.	2.8	14
15	Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck. Head and Neck, 2021, 43, 2807-2821.	2.0	4
16	Patterns and quality of care for head and neck cancer in Belgium: A populationâ€based study. European Journal of Cancer Care, 2021, 30, e13454.	1.5	4
17	Introduction of a New Pathology Workup Protocol for Glottic Cancer Treated With Transoral Laser Microsurgery (TLM): Prospective Analysis of Oncological Outcomes and Matched Case-Control Study. Frontiers in Oncology, 2021, 11, 685255.	2.8	2
18	Interobserver variability in organ at risk delineation in head and neck cancer. Radiation Oncology, 2021, 16, 120.	2.7	29

#	Article	IF	Citations
19	Ethanol-Induced Cell Damage Can Result in the Development of Oral Tumors. Cancers, 2021, 13, 3846.	3.7	7
20	The DNA Damage Response Is Differentially Involved in HPV-Positive and HPV-Negative Radioresistant Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 3717.	3.7	10
21	OC-0278 Accelerated CH-RT with/without nimorazole for p16- HNSCC: the randomized DAHANCA 29-EORTC 1219 trial. Radiotherapy and Oncology, 2021, 161, S187-S188.	0.6	7
22	Recurrence Patterns After IMRT/VMAT in Head and Neck Cancer. Frontiers in Oncology, 2021, 11, 720052.	2.8	6
23	Radiation Treatment for Inoperable Local Relapse of Parathyroid Carcinoma With Symptomatic Hypercalcemia: A Case Report. Frontiers in Oncology, 2021, 11, 733772.	2.8	1
24	Hypoxia and Its Influence on Radiotherapy Response of HPV-Positive and HPV-Negative Head and Neck Cancers, 2021, 13, 5959.	3.7	13
25	Learning from Mistakes: An Error-Driven Mechanism to Improve Segmentation Performance Based on Expert Feedback. Lecture Notes in Computer Science, 2021, , 68-77.	1.3	0
26	Segmentation of head-and-neck organs-at-risk in longitudinal CT scans combining deformable registrations and convolutional neural networks. Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization, 2020, 8, 519-528.	1.9	6
27	Radiosensitization approaches for HPVâ€positive and HPVâ€negative head and neck squamous carcinomas. International Journal of Cancer, 2020, 146, 1075-1085.	5.1	27
28	Comorbidity in head and neck cancer: Is it associated with therapeutic delay, post-treatment mortality and survival in a population-based study?. Oral Oncology, 2020, 102, 104561.	1.5	21
29	The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells. Scientific Reports, 2020, 10, 16208.	3.3	18
30	Ethanol exposure increases mutation rate through error-prone polymerases. Nature Communications, 2020, 11, 3664.	12.8	29
31	Transoral Laser Microsurgery (TLM) for Glottic Cancer: Prospective Assessment of a New Pathology Workup Protocol. Frontiers in Surgery, 2020, 7, 56.	1.4	6
32	Deep learning for elective neck delineation: More consistent and time efficient. Radiotherapy and Oncology, 2020, 153, 180-188.	0.6	21
33	Improved survival in patients with head and neck cancerÂtreated in higher volume centres: A population-based study in Belgium. European Journal of Cancer, 2020, 130, 81-91.	2.8	9
34	Study protocol for a randomized controlled trial: prophylactic swallowing exercises in head-and-neck cancer patients treated with (chemo)radiotherapyÂ(PRESTO trial). Trials, 2020, 21, 237.	1.6	20
35	Prognostic value of aÂ15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 552-560.	2.0	6
36	Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome. Radiotherapy and Oncology, 2020, 143, 24-29.	0.6	26

#	Article	IF	CITATIONS
37	PO-114 Variability in target volume delineation in Head and Neck cancer: Results of a national study. Radiotherapy and Oncology, 2019, 132, 58-59.	0.6	O
38	Does intensity-modulated radiation therapy lower the risk of osteoradionecrosis of the jaw? A long-term comparative analysis. International Journal of Oral and Maxillofacial Surgery, 2019, 48, 1387-1393.	1.5	18
39	EP-2026 Diffusion weighted textural differences between p16 positive and negative oropharyngeal carcinoma. Radiotherapy and Oncology, 2019, 133, S1111-S1112.	0.6	O
40	Head and Neck Cancer in Belgium: Quality of Diagnostic Management and Variability Across Belgian Hospitals Between 2009 and 2014. Frontiers in Oncology, 2019, 9, 1006.	2.8	6
41	PO-0723 Benefits of deep learning for delineation of organs at risk in head and neck cancer. Radiotherapy and Oncology, 2019, 133, S371.	0.6	O
42	Benefits of deep learning for delineation of organs at risk in head and neck cancer. Radiotherapy and Oncology, 2019, 138, 68-74.	0.6	79
43	Clinically Relevant Response to Cisplatin-5-Fluorouracyl in Intestinal-Type Sinonasal Adenocarcinoma with Loss of Vision: A Case Report. Case Reports in Oncology, 2019, 12, 277-281.	0.7	4
44	Interobserver variability in delineation of target volumes in head and neck cancer. Radiotherapy and Oncology, 2019, 137, 9-15.	0.6	59
45	Bilateral radiation-induced squamous cell carcinomas of the external auditory canal 30 years after radiotherapy for a pituitary adenoma: a case report. Tumori, 2019, 105, NP4-NP7.	1.1	0
46	Correlation of Patient- and Physician-Scored Dysphagia with Videofluoroscopies in Patients Treated with Radiotherapy for Head and Neck Cancer. Dysphagia, 2018, 33, 684-690.	1.8	3
47	Clinical factors impacting on late dysphagia following radiotherapy in patients with head and neck cancer. British Journal of Radiology, 2018, 91, 20180155.	2.2	4
48	In Regard to Bibault etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 100, 807-808.	0.8	1
49	Does the total dysphagia risk score correlate with swallowing function examined by videofluoroscopy?. British Journal of Radiology, 2018, 91, 20170714.	2.2	1
50	Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Reply to Elicin et al Radiotherapy and Oncology, 2018, 126, 571-572.	0.6	0
51	Volumetric modulated arc therapy of head-and-neck cancer on a fast-rotating O-ring linac: Plan quality and delivery time comparison with a C-arm linac. Radiotherapy and Oncology, 2018, 128, 479-484.	0.6	49
52	Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization. Radiotherapy and Oncology, 2018, 128, 161-166.	0.6	18
53	Clinical Implementation of DeepVoxNet for Auto-Delineation of Organs at Risk in Head and Neck Cancer Patients in Radiotherapy. Lecture Notes in Computer Science, 2018, , 223-232.	1.3	9
54	Toxicity Reduction in the Treatment of HPV Positive Oropharyngeal Cancer: Emerging Combined Modality Approaches. Frontiers in Oncology, 2018, 8, 439.	2.8	20

#	Article	IF	Citations
55	Low-Level Laser Therapy Stimulates Proliferation in Head and Neck Squamous Cell Carcinoma Cells. Frontiers in Oncology, 2018, 8, 343.	2.8	41
56	SP-0116: The status of reduced RT dose therapy for HPV + cancer. Radiotherapy and Oncology, 2018, 127, S60-S61.	0.6	0
57	OC-0491: CRISPR-Cas9 screen of DNA damage response reveals novel radiosensitizers for head and neck cancers. Radiotherapy and Oncology, 2018, 127, S252-S253.	0.6	0
58	OC-0514: VMAT treatment planning for head-and-neck cancer with the novel fast-rotating linac halcyon. Radiotherapy and Oncology, 2018, 127, S269-S270.	0.6	0
59	EP-1170: Clinical factors impacting on late dysphagia in head and neck cancer following radiotherapy. Radiotherapy and Oncology, 2018, 127, S655.	0.6	0
60	Prognostic Value of Stimulated Thyroglobulin Levels at the Time of Radioiodine Administration in Differentiated Thyroid Cancer. European Thyroid Journal, 2018, 7, 211-217.	2.4	13
61	Patient Selection in Human Papillomavirus Related Oropharyngeal Cancer: The Added Value of Prognostic Models in the New TNM 8th Edition Era. Frontiers in Oncology, 2018, 8, 273.	2.8	21
62	In Regard to Maguire etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 101, 746-747.	0.8	1
63	Recurrence patterns after a decreased dose of 40 Gy to the elective treated neck in head and neck cancer. Radiotherapy and Oncology, 2017, 123, 419-423.	0.6	25
64	Can sparing of the superficial contralateral parotid lobe reduce xerostomia following radiotherapy for head and neck cancer?. British Journal of Radiology, 2017, 90, 20170596.	2.2	5
65	SP-0398: Novel developments in the radiobiology of HPV-positive head and neck tumours. Radiotherapy and Oncology, 2017, 123, S212.	0.6	0
66	EP-1590: Can bolus range shifting improve plan quality in the IMPT of head and neck cancer?. Radiotherapy and Oncology, 2017, 123, S856-S857.	0.6	0
67	Dose de-escalation to the elective lymph nodes in head and neck cancer. Reply to Amdur et al Radiotherapy and Oncology, 2017, 124, 336.	0.6	0
68	OC-045: Recurrence patterns after 40 Gy to the elective treated neck in head and neck cancer Radiotherapy and Oncology, 2017, 122, 24-25.	0.6	0
69	The true value of altered fractionation in head and neck cancer. Lancet Oncology, The, 2017, 18, 1147-1148.	10.7	1
70	Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Tumor control and late toxicity. Radiotherapy and Oncology, 2017, 124, 220-224.	0.6	8
71	Dual role for p16 in the metastasis process of HPV positive head and neck cancers. Molecular Cancer, 2017, 16, 113.	19.2	18
72	Radiation dose escalation based on FDG-PET driven dose painting by numbers in oropharyngeal squamous cell carcinoma: a dosimetric comparison between TomoTherapy-HA and RapidArc. Radiation Oncology, 2017, 12, 59.	2.7	12

#	Article	IF	CITATIONS
73	Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control. Radiotherapy and Oncology, 2017, 122, 171-177.	0.6	56
74	Prognostic Significance of Glutathione Peroxidase Levels (GPx1) in Head and Neck Cancers. Frontiers in Oncology, 2017, 7, 84.	2.8	11
75	Can Intensity-Modulated-Radiotherapy Reduce Toxicity in Head and Neck Squamous Cell Carcinoma?. Cancers, 2017, 9, 135.	3.7	49
76	Up-front and Salvage Transoral Robotic Surgery for Head and Neck Cancer: A Belgian Multicenter Retrospective Case Series. Frontiers in Oncology, 2017, 7, 15.	2.8	29
77	Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers. Oncotarget, 2017, 8, 81662-81678.	1.8	61
78	Intensity modulated radiotherapy for head-and-neck cancer: discussing safety of modern radiation techniques. Translational Cancer Research, 2017, 6, S1043-S1048.	1.0	0
79	HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. Cancers, 2016, 8, 41.	3.7	100
80	Long-term follow-up of 123 patients with adenocarcinoma of the sinonasal tract treated with endoscopic resection and postoperative radiation therapy. Head and Neck, 2016, 38, 294-300.	2.0	71
81	Towards 3D printed multifunctional immobilization for proton therapy: Initial materials characterization. Medical Physics, 2016, 43, 5392-5402.	3.0	15
82	EP-1040: Development of a CT-based prognostic model for regional control in head and neck cancer after RT. Radiotherapy and Oncology, 2016, 119, S502-S503.	0.6	0
83	OC-0164: Integrate range shifting in immobilisation for proton therapy: 3D printed materials characterisation. Radiotherapy and Oncology, 2016, 119, S77.	0.6	0
84	SP-0393: The challenges of ART from a physician's perspective. Radiotherapy and Oncology, 2016, 119, S184.	0.6	1
85	OC-0439: Localization of p16 expression is an important factor to determine radiotherapy response in HNSCC. Radiotherapy and Oncology, 2016, 119, S204-S205.	0.6	0
86	OC-0452: Prospective randomized adaptive dose-de-escalation in the elective neck: late toxicity and control. Radiotherapy and Oncology, 2016, 119, S211-S212.	0.6	1
87	The role of stem cells in the prevention and treatment of radiationâ€induced xerostomia in patients with head and neck cancer. Cancer Medicine, 2016, 5, 1147-1153.	2.8	20
88	First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation. Journal of Chemotherapy, 2016, 28, 242-246.	1.5	14
89	PV-0517: Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy. Radiotherapy and Oncology, 2016, 119, S244-S245.	0.6	0
90	CT-based follow-up following radiotherapy or radiochemotherapy for locally advanced head and neck cancer; outcome and development of a prognostic model for regional control. British Journal of Radiology, 2016, 89, 20160492.	2.2	5

#	Article	IF	Citations
91	Differences in human papillomavirus–positive and –negative head and neck cancers in Belgium: an 8-year retrospective, comparative study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 121, 456-460.	0.4	16
92	Validation of the total dysphagia risk score (TDRS) in head and neck cancer patients in a conventional and a partially accelerated radiotherapy scheme. Radiotherapy and Oncology, 2016, 118, 293-297.	0.6	4
93	Nuclear p16INK4a expression predicts enhanced radiation response in head and neck cancers. Oncotarget, 2016, 7, 38785-38795.	1.8	12
94	Elevated carcinoembryonic antigen tumour marker caused by head and neck cancer: A case report and literature study. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2015, 19, 106-110.	1.4	0
95	Advances in Radiotherapy for Head and Neck Cancer. Journal of Clinical Oncology, 2015, 33, 3277-3284.	1.6	142
96	p16INK4a Impairs Homologous Recombination–Mediated DNA Repair in Human Papillomavirus–Positive Head and Neck Tumors. Cancer Research, 2014, 74, 1739-1751.	0.9	99
97	Quality assurance for the EORTC 22071–26071 study: dummy run prospective analysis. Radiation Oncology, 2014, 9, 248.	2.7	12
98	Redefining the target early during treatment. Can we visualize regional differences within the target volume using sequential diffusion weighted MRI?. Radiotherapy and Oncology, 2014, 110, 329-334.	0.6	17
99	Molecular Markers and Chemotherapy for Advanced Salivary Cancer. Current Otorhinolaryngology Reports, 2014, 2, 85.	0.5	7
100	Noncutaneous head and neck cancer in solid organ transplant patients: Single center experience. Oral Oncology, 2014, 50, 263-268.	1.5	10
101	Integrating pretreatment diffusion weighted MRI into a multivariable prognostic model for head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2014, 110, 429-434.	0.6	90
102	Using a Closed Analytical Expression to Determine Biological Effects Depending on Radiation Spectrum and Oxygen Level. International Journal of Radiation Oncology Biology Physics, 2013, 87, S97.	0.8	2
103	Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity. Radiotherapy and Oncology, 2013, 109, 323-329.	0.6	58
104	8515 POSTER DISCUSSION A Dose Escalation Study With Intensity Modulated Radiation Therapy (IMRT) in Moderately Advanced (T2N0, T2N1, T3N0) Squamous Cell Carcinomas (SCC) of the Oropharynx, Larynx and Hypopharynx Using a Simultaneous Integrated Boost (SIB) Approach. European Journal of Cancer, 2011, 47, S548.	2.8	0
105	P16 IMMUNOHISTOCHEMISTRY AND HPV-PCR FOR RESPONSE PREDICTION AFTER RADIOTHERAPY IN HNSCC. Radiotherapy and Oncology, 2011, 98, S10.	0.6	0
106	CORRELATION OF HPV STATUS TO PRETREATMENT FUNCTIONAL IMAGING IN PATIENTS WITH OROPHARYNGEAL CANCER. Radiotherapy and Oncology, 2011, 98, S44.	0.6	0
107	332 oral QUANTIFICATION OF DIFFUSION-WEIGHTED MRI FOR TREATMENT RESPONSE ASSESSMENT IN HEAD AND NECK CANCER. Radiotherapy and Oncology, 2011, 99, S132-S133.	0.6	0
108	836 poster FUNCTIONAL MR IMAGING IN PATIENTS WITH OROPHARYNGEAL CANCER AND THE RELATION TO HPV Radiotherapy and Oncology, 2011, 99, S325.	0.6	0

7

#	Article	IF	Citations
109	850 poster P16 IMMUNOHISTOCHEMISTRY AND HPV-PCR FOR RESPONSE PREDICTION AFTER RADIOTHERAPY IN HNSCC. Radiotherapy and Oncology, 2011, 99, S329-S330.	0.6	O
110	1120 poster MICROSCOPIC AND SPECTRAL DOSIMETRY USING GAF-CHROMIC FILMS AND SURFACE ELECTRON MICROSCOPY. Radiotherapy and Oncology, 2011, 99, S417-S418.	0.6	0
111	OP 75 An unbiased shRNA based lentiviral screen identifies tyrosine kinases that are important for survival and radioresistance in Head and Neck Squamous Cell Carcinoma. European Journal of Cancer, 2011, 47, S9-S10.	2.8	0
112	SU-E-T-105: Using GaF-Chromic Film to Determine Microscopic Dose Enhancement of Gold Nanoparticles. Medical Physics, 2011, 38, 3510-3510.	3.0	0
113	Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer., 2011, 7, 1-6.		12
114	Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. European Radiology, 2010, 20, 1703-1714.	4.5	182
115	Estimating Microscopic Dose Distribution Variations for Nano-particle Enhanced Radiation Therapy using GaF Chromic Film and Transmission Electron Microscopy (TEM). International Journal of Radiation Oncology Biology Physics, 2010, 78, S831-S832.	0.8	0
116	Postoperative accelerated radiotherapy (POPART) versus conventional postoperative radiotherapy (CPORT) in squamous cell head and neck cancer: A multicenter prospective randomized study of the Dutch Head and Neck Cooperative Study Group Journal of Clinical Oncology, 2010, 28, 5508-5508.	1.6	4
117	SU-GG-J-124: On the Search of the Ideal Radiation Source for Gold Nano-Particle Enhanced Radiation Treatment. Medical Physics, 2010, 37, 3174-3174.	3.0	O
118	Dose Prescription and Treatment Planning Based on [18F]FMISO-PET Hypoxia. International Journal of Radiation Oncology Biology Physics, 2009, 75, S617-S618.	0.8	0
119	Impact of Adding Concomitant Chemotherapy to Hyperfractionated Accelerated Radiotherapy for Advanced Head-and-Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1088-1095.	0.8	59
120	Dysphagia After Chemoradiotherapy for Head-and-Neck Squamous Cell Carcinoma: Dose–Effect Relationships for the Swallowing Structures. International Journal of Radiation Oncology Biology Physics, 2009, 75, 385-392.	0.8	163
121	DIFFUSION-WEIGHTED MRI (DWI)-GUIDED RADIOTHERAPY FOR HEAD AND NECK CANCER. Radiotherapy and Oncology, 2009, 92, S9-S10.	0.6	0
122	BIOLOGICALLY OPTIMISED IMRT BASED ON MOLECULAR IMAGING OF TUMOUR HYPOXIA. Radiotherapy and Oncology, 2009, 92, S199-S200.	0.6	0
123	Radiotherapy and chemoradiotherapy of the head and neck. , 2008, , 19-34.		0
124	P65 Radiosensitization by histone deacetylase inhibitors $+/\hat{a}^{2}$ demethylating agents in head and neck cancer cell lines. European Journal of Cancer, Supplement, 2007, 5, 23.	2.2	0
125	The prognostic value of FMISO and FDG pet in locally advanced head and neck cancer (HNC). Radiotherapy and Oncology, 2007, 82, S41.	0.6	O
126	109 Microsatellite alterations (MSI/LOH) in head and neck squamous cell carcinoma: Does a correlation exist with hypoxia as measured by pimonidazole?. Radiotherapy and Oncology, 2006, 78, S34.	0.6	O

Sandra Nuyts

#	Article	IF	CITATIONS
127	179 Microsatellite alterations in head and neck squamous cell carcinoma: comparison of the sensitivity of a novel literature-based microsatellite panel versus the bethesda reference panel. Radiotherapy and Oncology, 2006, 78, S61-S62.	0.6	O
128	Modern radiotherapy techniques versus three-dimensional conformal radiotherapy for head and neck cancer. The Cochrane Library, 0 , , .	2.8	4